Skip to main content
Contact Us
Subscribe
E-Edition
88°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aldeyra Therapeutics, Inc.
< Previous
1
2
Next >
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
February 23, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
February 16, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 09, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
February 07, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
December 21, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
December 13, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
December 01, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
November 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
November 03, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
October 26, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 06, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
September 14, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
September 07, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
August 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
July 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
July 12, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
July 11, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
June 09, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
June 08, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
June 07, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
May 24, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 23, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
May 18, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
May 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
May 04, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Chief Financial Officer Transition
April 28, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
April 27, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 21, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.